Meta-analysis Of Randomized Placebo-controlled Clinical Trials On Rasagiline Treatment Of Parkinson’s Disease

Objective:To assess the effectiveness and safety of rasagiline for Parkinson’sdisease.Methods:Literature databases including cochrane library,Web ofKnowledge(SCI),OVID(Medline),Pubmed,Wanfang Data,CNKI and VIP,and referencesand retrospective literature were searched.The date of search was from begining toOctober2012.The data of RCTs Meeting the inclusive criteria were extracted according toCochrane methods by two reviewers independently,and after the quality wasevaluated.Data analyzed by RevMan5.1software.Results:A total of six RCTs involving3269patients were included.The results ofmeta-analysis showed that:a)About effectiveness:compare with placebo,rasagiline2mg/dwas more effective in the treatment of early PD with significantdifferences(WMD=-3.16,95%CI:-3.21to-3.11,P<0.00001);compare with rasagiline1mg/d and2mg/d in treatment of early PD,a significant differences wasfound(WMD=0.15,95%CI:0.09to0.21,P<0.00001).b)About the safety:there was nosignificant differences between rasagiline and placebo in the incidence ofnausea’ headache and dizziness.conclusion:Rasagiline is effective of treatment in early Parkinson’s disease, the dosage1mg/d is better than2mg/d in treatment of early PD.And rasagiline has a well toleranceand safety.Further high-quality randomized controlled trials are needed to provide reliableevidence on the treatment of patients with Parkinson’s disease.